drugset / Trial / NCT02435862
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
Phase 2
Completed
105 enrolled
Allegro Ophthalmics, LLC
Duke University · collabTrial Runners, LLC · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
A Phase 2, Randomized, Double-masked, Placebo-controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy of Luminate in Inducing PVD in Subjects with Non-Proliferative Diabetic Retinopathy.
Timeline
- Start
- 2015-02-01
- Primary completion
- 2017-08-10
- Completion
- 2017-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risuteganib | Protein / enzyme biologic | 1 mg | — |
| Subject | Risuteganib | Protein / enzyme biologic | 2 mg | — |
| Subject | Risuteganib | Protein / enzyme biologic | 3 mg | — |